These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

183 related articles for article (PubMed ID: 11160664)

  • 1. Protective mucosal immunity to ocular herpes simplex virus type 1 infection in mice by using Escherichia coli heat-labile enterotoxin B subunit as an adjuvant.
    Richards CM; Aman AT; Hirst TR; Hill TJ; Williams NA
    J Virol; 2001 Feb; 75(4):1664-71. PubMed ID: 11160664
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immunoregulatory role of H-2 and intra-H-2 alleles on antibody responses to recombinant preparations of B-subunits of Escherichia coli heat-labile enterotoxin (rEtxB) and cholera toxin (rCtxB).
    Nashar TO; Hirst TR
    Vaccine; 1995 Jun; 13(9):803-10. PubMed ID: 7483801
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Induction of mucosal immunity against herpes simplex virus type 1 in the mouse protects against ocular infection and establishment of latency.
    Richards CM; Shimeld C; Williams NA; Hill TJ
    J Infect Dis; 1998 Jun; 177(6):1451-7. PubMed ID: 9607819
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Intranasal immunization against herpes simplex virus infection by using a recombinant glycoprotein D fused with immunomodulating proteins, the B subunit of Escherichia coli heat-labile enterotoxin and interleukin-2.
    Hazama M; Mayumi-Aono A; Miyazaki T; Hinuma S; Fujisawa Y
    Immunology; 1993 Apr; 78(4):643-9. PubMed ID: 8388365
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Protection against recurrent ocular herpes simplex virus type 1 disease after therapeutic vaccination of latently infected mice.
    Richards CM; Case R; Hirst TR; Hill TJ; Williams NA
    J Virol; 2003 Jun; 77(12):6692-9. PubMed ID: 12767989
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of adjuvant efficacy of herpes simplex virus type 1 recombinant viruses expressing TH1 and TH2 cytokine genes.
    Osorio Y; Ghiasi H
    J Virol; 2003 May; 77(10):5774-83. PubMed ID: 12719570
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Recombinant herpes simplex virus type 1 (HSV-1) codelivering interleukin-12p35 as a molecular adjuvant enhances the protective immune response against ocular HSV-1 challenge.
    Osorio Y; Ghiasi H
    J Virol; 2005 Mar; 79(6):3297-308. PubMed ID: 15731224
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Chimeras of labile toxin one and cholera toxin retain mucosal adjuvanticity and direct Th cell subsets via their B subunit.
    Boyaka PN; Ohmura M; Fujihashi K; Koga T; Yamamoto M; Kweon MN; Takeda Y; Jackson RJ; Kiyono H; Yuki Y; McGhee JR
    J Immunol; 2003 Jan; 170(1):454-62. PubMed ID: 12496431
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Immunopotency of the recombinant urease B subunit vaccine of Helicobacter pylori after intranasal administration to mice].
    Gao ZG; Zou QM; Guo G; Guo TS; Zou QM; Zeng WK; Xie QH
    Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi; 2003 Jan; 19(1):68-70. PubMed ID: 15132912
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mucosal and systemic antibody responses after peroral or intranasal immunization: effects of conjugation to enterotoxin B subunits and/or of co-administration with free toxin as adjuvant.
    Rask C; Fredriksson M; Lindblad M; Czerkinsky C; Holmgren J
    APMIS; 2000 Mar; 108(3):178-86. PubMed ID: 10752686
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Plasmid vectors encoding cholera toxin or the heat-labile enterotoxin from Escherichia coli are strong adjuvants for DNA vaccines.
    Arrington J; Braun RP; Dong L; Fuller DH; Macklin MD; Umlauf SW; Wagner SJ; Wu MS; Payne LG; Haynes JR
    J Virol; 2002 May; 76(9):4536-46. PubMed ID: 11932419
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Rotavirus 2/6 virus-like particles administered intranasally in mice, with or without the mucosal adjuvants cholera toxin and Escherichia coli heat-labile toxin, induce a Th1/Th2-like immune response.
    Fromantin C; Jamot B; Cohen J; Piroth L; Pothier P; Kohli E
    J Virol; 2001 Nov; 75(22):11010-6. PubMed ID: 11602741
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparative analysis of the mucosal adjuvanticity of the type II heat-labile enterotoxins LT-IIa and LT-IIb.
    Martin M; Metzger DJ; Michalek SM; Connell TD; Russell MW
    Infect Immun; 2000 Jan; 68(1):281-7. PubMed ID: 10603399
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immunization onto bare skin with heat-labile enterotoxin of Escherichia coli enhances immune responses to coadministered protein and peptide antigens and protects mice against lethal toxin challenge.
    Beignon AS; Briand JP; Muller S; Partidos CD
    Immunology; 2001 Mar; 102(3):344-51. PubMed ID: 11298834
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mucosal immunoadjuvant activity of recombinant Escherichia coli heat-labile enterotoxin and its B subunit: induction of systemic IgG and secretory IgA responses in mice by intranasal immunization with influenza virus surface antigen.
    Verweij WR; de Haan L; Holtrop M; Agsteribbe E; Brands R; van Scharrenburg GJ; Wilschut J
    Vaccine; 1998 Dec; 16(20):2069-76. PubMed ID: 9796066
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The mucosal adjuvanticity of two nontoxic mutants of Escherichia coli heat-labile enterotoxin varies with immunization routes.
    Park EJ; Chang JH; Kim JS; Yum JS; Chung SI
    Exp Mol Med; 2000 Jun; 32(2):72-8. PubMed ID: 10926118
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Adjuvant effect of non-toxic mutants of E. coli heat-labile enterotoxin following intranasal, oral and intravaginal immunization.
    De Magistris MT; Pizza M; Douce G; Ghiara P; Dougan G; Rappuoli R
    Dev Biol Stand; 1998; 92():123-6. PubMed ID: 9554265
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clostridium difficile toxin A carboxyl-terminus peptide lacking ADP-ribosyltransferase activity acts as a mucosal adjuvant.
    Castagliuolo I; Sardina M; Brun P; DeRos C; Mastrotto C; Lovato L; Palù G
    Infect Immun; 2004 May; 72(5):2827-36. PubMed ID: 15102793
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mucosal immunogenicity and adjuvant activity of the recombinant A subunit of the Escherichia coli heat-labile enterotoxin.
    De Haan L; Holtrop M; Verweij WR; Agsteribbe E; Wilschut J
    Immunology; 1999 Aug; 97(4):706-13. PubMed ID: 10457227
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Potency of a genetically detoxified mucosal adjuvant derived from the heat-labile enterotoxin of Escherichia coli (LTK63) is not adversely affected by the presence of preexisting immunity to the adjuvant.
    Ugozzoli M; Santos G; Donnelly J; O'Hagan DT
    J Infect Dis; 2001 Jan; 183(2):351-354. PubMed ID: 11110644
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.